StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report released on Tuesday. The brokerage issued a sell rating on the stock. Other research analysts have also issued reports about the stock. Benchmark decreased their price objective on shares of OncoCyte from $9.00 to $5.00 and set a speculative buy rating […]
OncoCyte (NASDAQ:OCX – Get Free Report) had its price objective lowered by investment analysts at Piper Sandler from $3.50 to $3.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm currently has a “neutral” rating on the stock. Piper Sandler’s target price suggests a potential downside of 10.18% from […]
StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report issued on Saturday morning. The brokerage issued a sell rating on the stock. Several other research firms also recently weighed in on OCX. Benchmark decreased their price target on shares of OncoCyte from $9.00 to $5.00 and set a speculative buy […]
StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note issued to investors on Sunday. The brokerage issued a sell rating on the stock. Other equities analysts also recently issued reports about the company. Needham & Company LLC cut their price objective on OncoCyte from $9.00 to $4.25 and set […]
StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research report report published on Sunday. The brokerage issued a sell rating on the stock. A number of other brokerages have also recently weighed in on OCX. Benchmark reduced their price target on OncoCyte from $9.00 to $5.00 and set a speculative […]